JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Kodu・Aktsiate loetelu・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

5.64 -3.75

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.64

Max

5.83

Põhinäitajad
By Trading Economics
Sissetulek	31M -172M
Müük	4.4M 19M
Kasumimarginaal	-899.843
Töötajad	800
EBITDA	44M -148M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+18.06% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. nov 2025

Turustatistika
By TradingEconomics
Turukapital	236M 2.8B
Eelmine avamishind	9.39
Eelmine sulgemishind	5.64

Uudiste sentiment

By Acuity

100%

358 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

4.15 / 4.75 Toetus ja vastupanu

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. okt 2025, 23:28 UTC

Kuumad aktsiad

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29. okt 2025, 23:07 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13%

30. okt 2025, 00:00 UTC

Tulu

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29. okt 2025, 23:40 UTC

Tulu

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29. okt 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29. okt 2025, 23:25 UTC

Tulu

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29. okt 2025, 22:51 UTC

Tulu

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29. okt 2025, 22:45 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29. okt 2025, 22:09 UTC

Tulu

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29. okt 2025, 22:08 UTC

Market Talk

Tulu

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29. okt 2025, 21:58 UTC

Tulu

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29. okt 2025, 21:58 UTC

Tulu

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29. okt 2025, 21:57 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29. okt 2025, 21:54 UTC

Tulu

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29. okt 2025, 21:46 UTC

Tulu

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29. okt 2025, 21:43 UTC

Tulu

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29. okt 2025, 21:43 UTC

Tulu

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29. okt 2025, 21:41 UTC

Tulu

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29. okt 2025, 21:40 UTC

Tulu

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29. okt 2025, 21:39 UTC

Tulu

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

18.06% tõus

12 kuu keskmine prognoos

Keskmine 6.93 USD 18.06%

Kõrge 8 USD

Madal 4.8 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Recursion Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

358 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.